Investigational and Unproven Therapies in Atopic Dermatitis

被引:7
作者
Ong, Peck Y. [1 ,2 ]
Boguniewicz, Mark [3 ,4 ]
机构
[1] Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA 90027 USA
[2] Univ So Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA 90089 USA
[3] Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA
[4] Univ Colorado, Sch Med, Denver, CO 80206 USA
关键词
Atopic dermatitis; Treatment; Experimental therapy; MYCOBACTERIUM-VACCAE SUSPENSION; SKIN BARRIER FUNCTION; ANTI-IGE THERAPY; STAPHYLOCOCCUS-AUREUS; CONTROLLED-TRIAL; DOUBLE-BLIND; CALCINEURIN INHIBITORS; SCRATCHING BEHAVIOR; SUPLATAST TOSILATE; VACCINIA VIRUS;
D O I
10.1016/j.iac.2010.05.002
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis can be a challenging disease to treat, often having a chronic or relapsing course. For patients with moderate to severe disease, it can result in significant morbidity and affect quality of life of patients or families. Current treatment can be associated with side effects or patient and caregiver concerns about use. Recent advances in the understanding of barrier defects and innate and adaptive immune systemic abnormalities in atopic dermatitis have provided potential new targets for therapeutic intervention. These advances include antimicrobial peptides, antistaphylococcal toxin strategies, Th2 cytokine inhibitors, and modulation of pruritus at the neuromediator level.
引用
收藏
页码:425 / +
页数:16
相关论文
共 93 条
  • [1] Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report
    Akdis, Cezmi A.
    Akdis, Mubeccel
    Bieber, Thomas
    Bindslev-Jensen, Carsten
    Boguniewicz, Mark
    Eigenmann, Philippe
    Hamid, Qutayba
    Kapp, Alexander
    Leung, Donald Y. M.
    Lipozencic, Jasna K.
    Luger, Thomas A.
    Muraro, Antonella
    Novak, Natalija
    Platts-Mills, Thomas A. E.
    Rosenwasser, Lanny
    Scheynius, Annika
    Simons, F. Estelle R.
    Spergel, Jonathan
    Turjanmaa, Kristiina
    Wahn, Ulrich
    Weidinger, Stefan
    Werfel, Thomas
    Zuberbier, Torsten
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (01) : 152 - 169
  • [2] Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
    Arellano, Felix M.
    Wentworth, Charles E.
    Arana, Alejandro
    Fernandez, Carlos
    Paul, Carle F.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (04) : 808 - 816
  • [3] Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages
    Arkwright, PD
    David, TJ
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (05) : 1029 - 1034
  • [4] Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease
    Arkwright, PD
    David, TJ
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (03) : 531 - 534
  • [5] Heliotherapy in atopic dermatitis: A prospective study on climatotherapy using the SCORAD Index
    Autio, P
    Komulainen, P
    Larni, HM
    [J]. ACTA DERMATO-VENEREOLOGICA, 2002, 82 (06) : 436 - 440
  • [6] A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis
    Behshad, Ramona
    Cooper, Kevin D.
    Korman, Neil J.
    [J]. ARCHIVES OF DERMATOLOGY, 2008, 144 (01) : 84 - 88
  • [7] Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels
    Belloni, Benedetta
    Ziai, Mahzad
    Lim, Annick
    Lemercier, Brigitte
    Sbornik, Martin
    Weidinger, Stephan
    Andres, Christian
    Schnopp, Christina
    Ring, Johannes
    Hein, Ruediger
    Ollert, Markus
    Mempel, Martin
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (05) : 1223 - 1225
  • [8] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
    Berth-Jones, J.
    Arkwright, P. D.
    Marasovic, D.
    Savani, N.
    Aldridge, C. R.
    Leech, S. N.
    Morgan, C.
    Clark, S. M.
    Ogilvie, S.
    Chopra, S.
    Harper, J. I.
    Smith, C. H.
    Rook, G. A. W.
    Friedmann, P. S.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09) : 1115 - 1121
  • [9] Treatment of pruritus with topically applied opiate receptor antagonist
    Bigliardi, Paul L.
    Stammer, Holger
    Jost, Gerhard
    Rufli, Theo
    Buchner, Stanislaw
    Bigliardi-Qi, Mei
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (06) : 979 - 988
  • [10] Boguniewicz Mark, 2007, J Drugs Dermatol, V6, P416